Atul Saran compensation by year
Emergent BioSolutions Summary Compensation Table · all 4 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|
| Salary | $283,179 | $488,730 | $503,774 | $528,803 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $462,457 | $527,475 | $619,984 | $700,047 |
| Option awards | $239,976 | $379,572 | $436,154 | $475,413 |
| Non-equity incentive | $180,380 | $293,567 | $293,567 | $445,204 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $54,562 | $8,683 | $9,500 | $9,565 |
| Total | $1,220,554 | $1,698,027 | $1,862,979 | $2,159,032 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Emergent BioSolutions Inc. DEF 14A filed April 9, 2021, accession 0001367644-21-000061, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Emergent BioSolutions Inc. filed document, accession 0001367644-21-000061. Every figure is read from that document and cited to the page and table it appears in. Filed April 9, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 5,697 | $510,451 | — |
| RSU | 5,697 | $510,451 | — |
| PSU | 5,697 | $510,451 | — |
| RSU | 5,313 | $476,045 | — |
| RSU | 5,081 | $455,258 | — |
| RSU | 3,387 | $303,475 | — |
| RSU | 1,771 | $158,682 | — |
| Option | 7,084 | — | $49.64 |
| Option | 13,554 | — | $61.01 |
| Option | 22,784 | — | $61.44 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Emergent BioSolutions Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
5 Form 4 lines since the FY2020 proxy (filed April 9, 2021)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2023-02-28 | Tax withholding | — | 971 | $12.38 | 86,645 |
| 2023-02-24 | Tax withholding | — | 845 | $13.71 | 87,616 |
| 2023-02-23 | Tax withholding | — | 365 | $14.30 | 88,461 |
| 2023-02-08 | Tax withholding | — | 2,051 | $13.25 | 88,826 |
| 2023-02-08 | Grant or award | — | 95 | $0.00 | 90,877 |
The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Emergent BioSolutions’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Robert Kramer | President and Chief Executive Officer | $5,569,978 |
| Fuad El-Hibri | Executive Chairman of the Board of Directors | $3,213,484 |
| Richard Lindahl | Executive Vice President, Chief Financial Officer and Treasurer | $2,281,300 |
| Adam Havey | Executive Vice President, Business Operations | $2,175,528 |
| Atul Saran · this page | Executive Vice President, Corporate Development, General Counsel and Secretary | $2,159,032 |
The full Emergent BioSolutions compensation record
free company briefThis page is one person within Emergent BioSolutions's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Emergent BioSolutions proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Emergent BioSolutions's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.